We’ve compiled summaries and reviews of four studies dealing with treatments indicated for squamous-cell NSCLC, breast cancer, and neuroendocrine tumors.
There are numerous opportunities to improve quality in the prescribing and monitoring of patients receiving oral anticancer medications.
As oncology medical organizations rally to increase awareness and promote the provision of better smoking cessation services to cancer patients, pharmacists have the opportunity to serve a vital role in this movement.
Cancer in women ages 15 to 19 years is relatively rare, but when it occurs, menstruation can result in clinically significant complications. During the care of hematologic malignancies, heavy menstrual bleeding in this patient population is commonly correlated with thrombocytopenia. The effects of chemotherapy, radiation, or bone marrow transplantation are also potential secondary causes of therapy-induced thrombocytopenia, leading to excessive menstrual bleeding.
Oral chemotherapy utilization and availability have increased in the past several years. Of the new oncologic agents in development, 30% to 35% are oral preparations.1 With the increasing development of new oral anticancer therapies, there have also been growing concerns regarding adherence, toxicity, and cost.

Results 1 - 5 of 5